On Thursday, in a statement Japan’s Fujifilm Holdings Corp said, it has signed a manufacturing contract with U.S.-based VLP Therapeutics for manufacturing a COVID-19 vaccine.

In a statement both companies said, “Fujifilm will use its manufacturing facilities and infrastructure to handle development of the vaccine for clinical trials”.

VLP’s RNA-based vaccine candidate was selected for funding by the Japan Agency for Medical Research and Development.

Ert h least decade, Fujifilm has increasingly drifted towards healthcare from its traditional photography and office solutions businesses.

Last month, it concluded a successful Phase-3 clinical trial of its Avigan drug for use in COVID-19 patients.

Categories: Creativity, Entrepreneurship, HR & Organization, Strategy

Tags: Avigan drug, clinical trial, clinical trials, coronavirus, COVID-19, development, financing, formulation, Fujifilm, Fujifilm Holdings Corp, funding, healthcare industry, infrastructure, Japan, Japan Agency, Japanese, making, manufacturing, manufacturing contract, manufacturing facilities, Medical Research and Development, patients, phase 3, RNA based, successful, U.S., United States, US, vaccine, vaccine candidate, VLP Therapeutics, Wuhan